Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Operating Expenses for 6 consecutive years, with $61.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 19.83% to $61.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $230.5 million, a 36.88% increase, with the full-year FY2024 number at $187.9 million, up 40.64% from a year prior.
  • Operating Expenses was $61.3 million for Q3 2025 at 4D Molecular Therapeutics, up from $59.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $61.3 million in Q3 2025 to a low of $18.3 million in Q1 2021.
  • A 5-year average of $36.8 million and a median of $32.4 million in 2023 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 57.69% in 2021; the steepest drop was 8.92% in 2021.
  • 4D Molecular Therapeutics' Operating Expenses stood at $24.9 million in 2021, then grew by 20.56% to $30.0 million in 2022, then rose by 22.24% to $36.6 million in 2023, then soared by 53.19% to $56.1 million in 2024, then rose by 9.19% to $61.3 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Operating Expenses are $61.3 million (Q3 2025), $59.5 million (Q2 2025), and $53.6 million (Q1 2025).